Skip to main navigation
Pharvaris N.V. Logo
  • Careers
  • Investors & Media
  • Contact
  • SCIENCE
  • PIPELINE
  • DISEASE FOCUS
  • HAE COMMUNITY
  • CLINICAL TRIALS
  • ABOUT US

Event Details

Investor Menu

IR Nav

  • Overview
  • News & Events
    News Releases Events Publications
  • Financials
    SEC Filings Quarterly Results
  • Stock
    Stock Performance Analyst Coverage
  • Corporate Governance
    Governance Documents Leadership Board of Directors Committee Composition
  • Resources
    Investor FAQs Contact Us Email Alerts

13th C1-inhibitor Deficiency and Angioedema Workshop

May 4 - May 7, 2023

Supporting Materials

Deucrictibant Data Highlighted in Multiple Presentations at the C1-Inhibitor Deficiency and Angioedema Workshop
The EC85 Derived from the Oral Bradykinin B2 Receptor Antagonist Deucrictibant (PHA121) Against Bradykinin Effects in Healthy Volunteers Predicts the Onset and Duration of Its Clinical Effects in Hereditary Angioedema 1.1 MB
Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate Release Capsule (PHVS416) in Treatment of Hereditary Angioedema Attacks: Topline Results of RAPIDe 1 Phase 2 Trial 870.7 KB
Early symptom relief following treatment with the oral bradykinin 2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in patients with hereditary angioedema attacks 850.4 KB
Cardiovascular safety of the orally administered bradykinin B2 receptor antagonist, deucrictibant (PHA121, PHA-022121) 1.1 MB
Efficacy of the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) by attack location in the RAPIDe-1 phase 2 clinical trial for treatment of hereditary angioedema attacks 1.6 MB
Pharvaris N.V. Logo

CONTACT US

FOLLOW US

linkedin logo

©2023 Pharvaris N.V. © All Rights Reserved

  • Privacy Policy
  • Terms of Use